Lifestyle Delivery Systems is planning to conduct clinical trials in Canada to obtain patent for its CannaStrips formula.
The CannaStrips formula is based on nano-engineered technology, the delivery system features low-viscosity pores or temporary channels for rapid transport of therapeutic molecules, including cannabis-derived bioactives, across the oral mucous barrier for systemic delivery from the buccal surface into the bloodstream.
Each particle is coated with a nano-envelope which chaperones its cargo to target tissues within the body.
The trials will be conducted to establish efficacy of the CannaStrip delivery system, following which the company will submit results of the clinical trials to the Canadian health officials to be recognised as an alternative delivery method for medicinal marijuana in Canada.
It will primarily focus on determining the time taken by the delivery system from being applied onto the buccal membrane to releasing the active ingredients into the blood stream.
Secondly, the trial will also determine the amount of active ingredients delivered into the blood stream and duration until which the ingredients will remain bioavailable in the blood stream to the patient and the extent to which the ingredients will be released to specific areas of the body and brain.
Lifestyle Delivery Systems chief medical officer John Sanderson said: "While edibles overcome the health and safety issues of inhalation as a method of cannabis delivery, they are inherently far less efficient, as much of the therapeutic effect of the plant is lost to incomplete absorption and early liver disposal.
“These clinical investigations are an exciting next step that takes us from the laboratory trials to a more rigorous examination of the incremental benefits of this unique system of delivery which provides a third option that addresses concerns about both safety and efficacy."